View clinical trials related to MSI-H Colorectal Cancer.
Filter by:- Microsatellite instable (MSI) tumors represent almost the 15% of all sporadic colorectal cancers (CRCs). - Literature data show that this unique tumor population appears to be poorly responsive to conventional chemotherapy and conversely reveals excellent results to immunotherapy. - Our data, as demonstrated by propensity score-matched and win ratio analysis, show that there are no substantial differences between MSI and MSS tumors in early CRC stages treated with surgery alone. - On the contrary, stable tumors (MSS) did much better than MSI tumors in advanced CRC stages undergoing conventional adjuvant treatment. - Determination of status of DNA mismatch repair system is crucial in high-risk CRCs to optimize treatment.
This is an open-label, non-randomized, multicenter, dose-escalation and expansion study in patients with selected solid tumors.